Latest Information Update: 08 Feb 2005
At a glance
- Originator AlphaRx
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 08 Feb 2005 Discontinued - Preclinical for Immunological disorders in Canada (unspecified route)
- 08 Nov 2001 New profile
- 08 Nov 2001 Preclinical development for Immunological disorders in Canada (Unknown route)